Literature DB >> 32602291

Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells.

S V Antonenko1, G D Telegeev1.   

Abstract

AIM: To analyze interaction of ubiquitin specific peptidase 1 (USP1) with Bcr-Abl and to assess the relation between USP1 functional activity and Bcr-Abl expression in K562 chronic myeloid leukemia cells.
MATERIALS AND METHODS: The interaction between USP1 and Bcr-Abl in K562 cells was analyzed by co-immunoprecipitation, Western blot analysis, and confocal microscopy.
RESULTS: A direct interaction between Bcr-Abl oncoprotein and USP1 protein in K562 cells was established by co-immunoprecipitation. Immunofluorescence analysis and confocal microscopy revealed that Bcr-Abl/USP1 protein complex is formed in the cell nucleus. The inhibition of USP1 protein activity by ML323 reduced the level of Bcr-Abl oncoprotein in K562 cells.
CONCLUSIONS: USP1 protein has been identified as a new protein partner of Bcr-Abl oncoprotein in chronic myeloid leukemia. The relationship between the functional activity of USP1 protein and the level of Bcr-Abl oncoprotein has been demonstrated, suggesting that the targeted inhibition of USP1 activity could be a challenging approach for reducing Bcr-Abl expression.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32602291     DOI: 10.32471/exp-oncology.2312-8852.vol-42-no-2.14533

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  2 in total

1.  A Gene Transfer-Positive Cell Sorting System Utilizing Membrane-Anchoring Affinity Tag.

Authors:  Lele Yang; Lifang Cui; Shumin Ma; Qingqing Zuo; Qilai Huang
Journal:  Front Bioeng Biotechnol       Date:  2022-06-16

2.  The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner.

Authors:  Muhammad Shahzad Ali; Cristina Panuzzo; Chiara Calabrese; Alessandro Maglione; Rocco Piazza; Daniela Cilloni; Giuseppe Saglio; Barbara Pergolizzi; Enrico Bracco
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.